Drug Trial News

RSS

New targeted therapy zolbetuximab extends survival for patients with advanced gastric cancer

An international phase 3 clinical trial, done in participation with Weill Cornell Medicine and NewYork-Presbyterian, found that a new targeted treatment called zolbetuximab, given in combination with a standard chemotherapy, extended survival for patients with advanced gastric or gastroesophageal junction cancer that overexpressed a specific biomarker.

23 Aug 2023

$9.57 million grant will support a clinical trial to study new treatment option for NAFLD

According to the National Institutes of Health, approximately 24% of adults in the United States have nonalcoholic fatty liver disease (NAFLD), an umbrella term for a range of liver conditions affecting people who drink little to no alcohol that can lead to cirrhosis, liver cancer and liver failure.

23 Aug 2023

Phase I trial shows positive results for stem cell treatment in patients with major cornea injuries

A team led by researchers from Mass Eye and Ear, a member of Mass General Brigham, reports the results of a phase I trial of a revolutionary stem cell treatment called cultivated autologous limbal epithelial cell transplantation (CALEC), which was found to be safe and well-tolerated over the short term in four patients with significant chemical burns in one eye.

18 Aug 2023

Medicaid expansion increases cancer clinical trial participation

The Medicaid expansion under the Patient Protection and Affordable Care Act resulted in a 19% annual increase in Medicaid-insured cancer patients participating in publicly funded clinical trials, according to researchers from Fred Hutchinson Cancer Center, the SWOG Statistics and Data Management Center and Columbia University.

18 Aug 2023

Phase I trial shows promise: Brain stimulation spurs upper-extremity recovery in stroke patients

Researchers performed an open-label phase I trial.

18 Aug 2023

New drug candidate nearly doubles survival for patients with aggressive childhood brain tumors

For the first time, researchers have found a potential drug candidate that improved outcomes for patients with a type of childhood brain tumor for which there are no effective treatments.

17 Aug 2023

Levonorgestrel-piroxicam co-treatment shows promise as more effective emergency contraception

Taking piroxicam, an anti-inflammatory medication commonly used for arthritis pain, at the same time as the levonorgestrel emergency contraceptive pill after unprotected sex prevents significantly more pregnancies compared to taking levonorgestrel alone, according to a randomised controlled trial published in The Lancet.

17 Aug 2023

Insilico Medicine's new AI tool shows promise in predicting clinical trial outcomes

Insilico Medicine ("Insilico"), a clinical-stage end-to-end generative artificial intelligence (AI) drug discovery company, has demonstrated that it can predict the outcome of Phase II to Phase III clinical trial success using its proprietary transformer-based AI clinical trial prediction tool called inClinico with a high degree of accuracy.

3 Aug 2023

Kombucha may help lower blood sugar levels in people with type 2 diabetes

People with type-II diabetes who drank the fermented tea drink kombucha for four weeks had lower fasting blood glucose levels compared to when they consumed a similar-tasting placebo beverage, according to results from a clinical trial conducted by researchers at Georgetown University's School of Health, the University of Nebraska-Lincoln and MedStar Health.

1 Aug 2023

NIH launches and opens enrollment for phase 2 clinical trials to evaluate long COVID treatments

Today, the National Institutes of Health launched and is opening enrollment for phase 2 clinical trials that will evaluate at least four potential treatments for long COVID, with additional clinical trials to test at least seven more treatments expected in the coming months.

31 Jul 2023

Trial evaluates purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder

Researchers investigated the safety and pharmacokinetics of JNJ-54175446 in a double-blind, multicenter, randomized controlled trial (RCT).

31 Jul 2023

New class of antibody could benefit patients with treatment-resistant cancers

A Cancer Research UK-funded clinical trial has shown, for the first time, that a new class of antibody could benefit cancer patients whose existing treatments have stopped working.

28 Jul 2023

Broad-spectrum influenza vaccine candidate shows safety, immunogenicity data across three dose levels

Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that The Lancet Infectious Diseases published results from the company's OVX836-003 study under the title, "Immunogenicity, safety and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate: randomized, double-blind placebo-controlled, Phase 2a trial."

27 Jul 2023

Exclusion of chronic kidney disease patients from cardiovascular trials leaves significant evidence gaps

Study looks at how and where patients with CKD have been excluded from CVD RCTs over the last two decades.

24 Jul 2023

ECOG-ACRIN launches new trial to evaluate nilotinib and paclitaxel for advanced cancers

The ECOG-ACRIN Cancer Research Group has enrolled the first patient in a new treatment trial to evaluate the effectiveness of adding nilotinib to standard paclitaxel chemotherapy.

20 Jul 2023

New brain-penetrant agonist shows promise in protecting dopamine neurons for Parkinson's disease treatment

Researchers reported on Nurr1 as a promising therapeutic target for managing Parkinson's disease (PD).

20 Jul 2023

Donanemab: A trailblazer for Alzheimer's disease treatment?

A recent study evaluated the efficacy and side effects of donanemab, an antibody that could possibly clear brain amyloid plaque in early symptomatic Alzheimer disease (AD).

20 Jul 2023

Donanemab may offer new hope for people with early Alzheimer's disease

The data reported today by Eli Lilly from the TRAILBLAZER-ALZ 2 clinical trial of donanemab in early symptomatic Alzheimer's disease demonstrate an important advancement in Alzheimer's research and treatment.

17 Jul 2023

PALACE study: Direct oral challenge can safely remove penicillin allergy label

Penicillin allergy affects more than 25 million people in the United States (up to 1 in 10 Americans) and has been shown to lead to particularly poor health outcomes in pregnant women and surgical patients. It is also a public health threat, leading to antibiotic resistance and infections in hospitalized patients that can be life threatening.

17 Jul 2023

Donanemab shows promise in slowing Alzheimer's disease

With yet a third new Alzheimer's drug expected to be approved by the Food and Drug Administration (FDA), the field is beginning to show progress in the fight to slow the disease.

17 Jul 2023

Previous
1
...
8
9
10
11
12
13
14
...
1135
Next

Drug Trial News

New targeted therapy zolbetuximab extends survival for patients with advanced gastric cancer

$9.57 million grant will support a clinical trial to study new treatment option for NAFLD

Phase I trial shows positive results for stem cell treatment in patients with major cornea injuries

Medicaid expansion increases cancer clinical trial participation

Phase I trial shows promise: Brain stimulation spurs upper-extremity recovery in stroke patients

New drug candidate nearly doubles survival for patients with aggressive childhood brain tumors

Levonorgestrel-piroxicam co-treatment shows promise as more effective emergency contraception

Insilico Medicine's new AI tool shows promise in predicting clinical trial outcomes

Kombucha may help lower blood sugar levels in people with type 2 diabetes

NIH launches and opens enrollment for phase 2 clinical trials to evaluate long COVID treatments

Trial evaluates purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder

New class of antibody could benefit patients with treatment-resistant cancers

Broad-spectrum influenza vaccine candidate shows safety, immunogenicity data across three dose levels

Exclusion of chronic kidney disease patients from cardiovascular trials leaves significant evidence gaps

ECOG-ACRIN launches new trial to evaluate nilotinib and paclitaxel for advanced cancers

New brain-penetrant agonist shows promise in protecting dopamine neurons for Parkinson's disease treatment

Donanemab: A trailblazer for Alzheimer's disease treatment?

Donanemab may offer new hope for people with early Alzheimer's disease

PALACE study: Direct oral challenge can safely remove penicillin allergy label

Donanemab shows promise in slowing Alzheimer's disease

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News